Sunvozertinib (DZD9008) has demonstrated activity in patients with non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation across mutation types and prior treatments, according to data pooled from 3 phase 1/2 clinical trials. Findings from the clinical trials were presented at the International Associationfor the Study of Lung Cancer 2022 North America Conference on Lung Cancer.1
“Sunvozertinib…has compelling clinical efficacy in patients with non–small cell lung cancer who received prior platinum [therapy] and have an EGFR exon 20 insertion,” Lyudmila A. Bazhenova, MD, said in a presentation of the updated findings at the conference.
Bazhenova is professor of medicine at Moores Cancer Center at UC San Diego Health in California.
Bazhenova noted that sunvozertinib is an EGFR exon 20 insertion inhibitor with selectivity for wild-type EGFR as well. The agent received a breakthrough therapy designation from the FDA and the Chinese National Medical Products Administration as a treatment for patients with NSCLC and EGFR exon 20 insertion mutation whose disease has progressed during or after platinum-based chemotherapy.2
Three clinical trials explored sunvozertinib, including WU-KONG1 (NCT03974022), an international phase 1/2 study with ongoing enrollment; WU-KONG2 (CTR20192097), a phase 1 study conducted in China; and WU-KONG6 (CTR20211009), a pivotal phase 2 study conducted in China. All patients in the 3 studies had locally advanced or metastatic NSCLC with an EGFR or HER2 mutation and adequate organ system function. Patients with brain metastases were allowed to participate in the study if the metastasis was stable. Treatment was administered in the studies at doses between 50 mg and 400 mg. Read more.